Canaan unveils $800M fund for fresh wave of biotech bets

Canaan's fund is close to 20% bigger than its previous investment vehicle

Canaan has put together an $800 million investment fund. The fund positions Canaan to place a fresh round of bets on early-stage biotechs, continuing the strategy that has delivered it paydays as companies including Johnson & Johnson and Teva have snapped up pieces of its portfolio.

In keeping with the strategy it has followed over its 30-year history, Canaan will split the latest fund between tech and biotech. Today, about 40% of Canaan’s cash goes into biotech and medical technology, the Wall Street Journal reports, suggesting its 11th fund could funnel about $320 million into developers of drugs and devices. Given Canaan invests early, that positions plenty of biotechs to land investments from the VC shop.

Canaan’s $800 million fund is close to 20% bigger than its 10th fund. The step up in size resulted from the desire of backers of the previous fund to collectively commit about 50% more and from the interest of new limited partners.  


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

This level of interest reflects Canaan’s successes—two of its past three vehicles have been among the top VC performers—and a broader trend for big investors to get bigger. Fellow tech-biotech investor New Enterprise Associates set the tone when it raised $3.3 billion for its latest fund. And Canaan has now added to evidence limited partners are clustering behind proven prospects.   

“It feels like people are saying, we want to double down on the winners,” Maha Ibrahim, a managing partner at Canaan, told the WSJ. “It’s a very active environment.”

Canaan has established itself in the winner’s circle through investments in companies such as Civitas Therapeutics, Labrys Biologics and Novira Therapeutics. Acorda Therapeutics bought Civitas for $525 million in cash. Teva bought Labrys for $200 million upfront to join the competitive CGRP migraine race. And J&J bought Novira for an undisclosed sum to acquire its hepatitis B virus. 

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.